首页> 外文期刊>Biomedical materials >In-vitro assessment of beta-tricalcium phosphate/bredigite-ciprofloxacin (CPFX) scaffolds for bone treatment applications
【24h】

In-vitro assessment of beta-tricalcium phosphate/bredigite-ciprofloxacin (CPFX) scaffolds for bone treatment applications

机译:对β-三磷酸钙/ BREDIGITE-CIPROFloxac(CPFX)支架进行骨处理应用的体外评估

获取原文
获取原文并翻译 | 示例
           

摘要

In the present study, beta-tricalcium phosphate (beta-TCP) scaffolds with various amounts of bredigite (Bre) were fabricated by the space holder method. The effect of bredigite content on the structure, mechanical properties, in vitro bioactivity, and cell viability was investigated. The structural assessment of the composite scaffolds presented interconnected pores with diameter of 300-500 mu m with around 78%-82% porosity. The results indicated that the compressive strength of the scaffolds with 20% bredigite (1.91 MPa) was improved in comparison with scaffolds with 10% bredigite (0.52 MPa), due to the reduction of the average pore and grain sizes. Also, the results showed that the bioactivity and biodegradability of beta-TCP/20Bre were better than that of beta-TCP/10Bre. Besides, in this study, the release kinetics of ciprofloxacin (CPFX) loaded beta-TCP/Bre composites as well as the ability of scaffolds to function as a sustained release drug carrier was investigated. Drug release pattern of beta-TCP/bredigite-5CPFX scaffolds exhibited the rapid burst release of 43% for 3 h along with sustained release (82%) for 32 h which is favorable for bone infection treatment. Antibacterial tests revealed that the antibacterial properties of beta-TCP/bredigite scaffolds are strongly related to the CPFX concentration, wherein the scaffold containing 5% CPFX showed the most significant zone of inhibition (33 +/- 0.5 mm) against Staphylococcus aureus. The higher specific surface areas of nanostructure beta-TCP/bredigite scaffolds containing CPFX lead to an initial rapid release followed by constant drug delivery. MTT assay showed that the cell viability of beta-TCP/bredigite scaffold loading with up to 1%-3% CPFX (95 +/- 2%), is greater than for scaffolds containing 5% CPFX (84 +/- 2%). In Overall, it may suggested that beta-TCP/bredigite containing 1%-3% CPFX possesses great cell viability and antibacterial activity and be employed as bactericidal biomaterials and bone infection treatment.
机译:在本研究中,通过空间保持器方法制造具有各种量Bredigite(BRE)的β-三磷酸钙(β-TCP)支架。已经研究了Bredigite含量对结构,机械性能,体外生物活性和细胞活力的影响。复合支架的结构评估呈现直径为300-500μm的相互连接的孔,孔隙率约为78%-82%。结果表明,由于平均孔隙和晶粒尺寸的降低,与具有10%Bredigite(0.52MPa)的支架进行改善,改善了具有20%Bredigite(1.91MPa)的支架的抗压强度。此外,结果表明,β-TCP / 20BRE的生物活性和生物降解性优于β-TCP / 10BRE的生物活性和生物降解性。此外,在本研究中,研究了环丙沙星(CPFX)的释放动力学,所述β-TCP / BRE复合材料以及支架用作持续释放药物载体的能力。 β-TCP / BREDIGITE-5CPFX支架的药物释放模式表现出3小时的快速爆发释放,32小时,32小时的持续释放(82%),这是有利的骨感染处理。抗菌试验表明,β-TCP / BREDIGITE支架的抗菌性能与CPFX浓度强烈有关,其中含有5%CPFX的支架显示出对金黄色葡萄球菌的最重要的抑制区(33 +/- 0.5mm)。含有CPFx的纳米结构β-TCP / Bredigite支架的纳米结构β-TCP / Bredigite支架的较高的表面积导致初始快速释放,然后持续递送。 MTT测定表明,β-TCP / Bredigite支架载荷的细胞活力高达1%-3%CpFx(95 +/- 2%),大于含有5%CpFx的支架(84 +/- 2%) 。总的来说,可能表明含有1%-3%CPFX的β-TCP / BREDIGITE具有很大的细胞活力和抗菌活性,并用作杀菌生物材料和骨感染处理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号